Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
15 Results for "
primary human PBMCs
" in MedChemExpress (MCE) Product Catalog:
Products (15)
15 Results for "primary human PBMCs" in MCE Product Catalog:
1
Zelebrudomide is an orally active BTK-targeting PROTAC degrader, with DC50 values of 4.5 nM and 31 nM against wild-type BTK and BTK C481S mutant, respectively. Zelebrudomide recruits the cereblon E3 ubiquitin ligase complex to mediate the degradation of BTK. Zelebrudomide also acts as a molecular glue to bind the cereblon E3 ubiquitin ligase complex, mediating the degradation of IKZF1 and IKZF3. Zelebrudomide can be used in the research of B-cell malignancies .
1
1 Cited Publications
Research Areas:
ML345 is a potent and selective inhibitor of insulin-degrading enzyme (IDE) and NLRP3, with an IC50 of 188 nM against IDE. ML345 targets the Cys819 residue of IDE to inhibit IDE. ML345 selectively binds to NLRP3 in a non-covalent manner. ML345 inhibits inflammatory cytokines (IL-1β, IL-6) and exhibits potent anti-inflammatory activity. ML345 exerts a protective effect against miscarriage .
Cat. No.: HY-P11072
CAS No.: 1601299-92-6
Research Areas:
Research Areas:
NOD2 antagonist 1 is a selective NOD2 antagonist with an IC50 of 5.23 μM. NOD2 antagonist 1 acts directly on the NOD2 protein, downregulates the secretion of pro-inflammatory cytokines such as IL-8 and TNF-α, and inhibits the synergistic cross-response of inflammation mediated by NOD2 and TLR4. NOD2 antagonist 1 can be used in studies related to immunity and inflammation .
Cat. No.: HY-119715
CAS No.: 486414-35-1
Research Areas:
AG-012986 is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
Cat. No.: HY-162465
CAS No.: 335401-44-0
BDW568 is a selective STING A230 agonist with an EC50 of 5.7 μM. BDW568 triggers the interferon signaling pathway and induces the expression of interferon-stimulated genes including MX1 and OAS1. BDW568 is applicable for cancer-related research .
Cat. No.: HY-171692
CAS No.: 2780391-08-2
Target:
Research Areas:
G3-YSD is a cGAS agonist. G3-YSD directly interacts with cGAS to enhance its enzymatic activity, promote the conversion of ATP and GTP into cGAMP, and trigger STING-dependent IFN-α/β secretion. G3-YSD acts as a viral mimic to replace actual viral DNA . G3-YSD is applicable to research related to long COVID and type 1 human immunodeficiency virus infection .
Cat. No.: HY-153220A
CAS No.: 3024312-52-2
Synonyms: (R)-NX-2127
Research Areas:
(R)-Zelebrudomide ((R)-NX-2127) is an isomer of Zelebrudomide (HY-153220). Zelebrudomide is an orally active BTK-targeting PROTAC degrader, with DC50 values of 4.5 nM and 31 nM against wild-type BTK and BTK C481S mutant, respectively. Zelebrudomide recruits the cereblon E3 ubiquitin ligase complex to mediate the degradation of BTK. Zelebrudomide also acts as a molecular glue to bind the cereblon E3 ubiquitin ligase complex, mediating the degradation of IKZF1 and IKZF3. Zelebrudomide can be used in the research of B-cell malignancies .
Cat. No.: HY-168074
Target:
Research Areas:
4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .
Cat. No.: HY-184441
CAS No.: 3116073-35-6
Target:
Research Areas:
CD28-IN-4 is a selective CD28 inhibitor with a human IC50 of 231 nM and a human Kd of 344 nM. CD28-IN-4 binds to CD28, disrupts its interaction with CD80, blocks CD28-mediated co-stimulatory signal transduction, and reduces cytokine secretion in a human primary tumor-PBMC and epithelial tissue co-culture model. CD28-IN-4 can be used for cancer-related research .
Cat. No.: HY-182470
CAS No.: 486414-32-8
Target:
AG-012986 (dihydrochloride) is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 (dihydrochloride) causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 (dihydrochloride) induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 (dihydrochloride) exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 (dihydrochloride) can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
Cat. No.: HY-182928
CAS No.: 3018825-60-7
Research Areas:
LRRK2-IN-21 is a selective, blood-brain barrier-permeable LRRK2 kinase inhibitor with an IC50 of 0.35 nM. LRRK2-IN-21 inhibits TTK kinase with an IC50 of 70 nM. LRRK2-IN-21 is applicable to the research of Parkinson's disease .
Cat. No.: HY-185821
Research Areas:
CD388 is an antiviral reagent-Fc conjugate formed by linking an influenza virus neuraminidase inhibitor to the CH1-Fc hybrid domain of IgG1. CD388 exerts antiviral activity extracellularly by inhibiting Neuraminidase. CD388 reduces pulmonary viral load and proinflammatory cytokine levels in influenza-infected mice, prevents death, reduces body weight loss, and prolongs median time to death. CD388 exhibits activity against influenza A and B subtypes, including highly pathogenic strains. CD388 can be used in influenza-related research .
Cat. No.: HY-P10466
CAS No.: 2377734-91-1
Research Areas:
Cat. No.: HY-182456
CAS No.: 1426319-74-5
Target:
Research Areas:
CHDI-340246 is an orally active kynurenine monooxygenase (KMO) inhibitor. CHDI-340246 blocks KMO activity, alters the metabolic flux of the kynurenine pathway, inhibits the production of 3-hydroxykynurenine and quinolinic acid, elevates the levels of kynurenine and kynurenic acid, and restores electrophysiological abnormalities in transgenic mouse models of Huntington's disease. CHDI-340246 can be used in studies related to Huntington's disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
